Bioprinting technology plays a major role in developing biomimetic tissue models for drug-screening and toxicity testing. In the recently funded EU-project “Taktira”, led by Syntab Therapeutics, a new class of immuno-oncologics are developed and validated. The research consortium comprises eight partners from academia and industry: Syntab Therapeutics (Würselen), Gremse-IT (Aachen), TECO Development (Rheinbach), and Black Drop Biodrucker (Aachen), as well as the Institute of Laboratory Animal Science, the Institute for Experimental Molecular Imaging and the Clinic for Gynaecology of the University Hospital RWTH Aachen as well as the Institute for Biological Chemistry of the University of Vienna. The consortium investigates a new class of immuno-oncologics that activate the innate immune system and at the same exhibit higher efficacy and better bioavailability than existing compounds. Black Drop supports the consortium with 3D-bioprinting technology and expertise on the biofabrication of vascularized tumor models.
Trans Tech Diagnostics (TTD) focuses on the development of better options for the identification of cardiovascular diseases. TTD is an Interreg Vlaanderen-Nederland innovation project with a total budget of 3,160,000 € to which Interreg makes a contribution of 1,580,000 € (50 %, ERDF).
The partners Universiteit Maastricht (CARIM, lead partner), Universiteit Hasselt (BIOMED), VITO, TSG InnoteQ, PimBio, Tenco DDM, DSP Valley, BONNÉ+JAN and Black Drop Biodrucker GmbH focus in the Interreg Vlaanderen-Nederland project Trans Tech Diagnostics (TTD) on the development of better options for the identification of cardiovascular diseases.
Cardiovascular diseases are the number one cause of death and cost the European community €196 billion a year. Of this, €106 billion is spent on healthcare (diagnostics and treatment). The rapid ageing and dejuvenation in our border region creates the expectation that cardiovascular disease will have a strongly increasing negative impact on our society.
Many people with cardiovascular disease do not show any serious symptoms during the development of the disease and are therefore without treatment. However, they have a higher risk of having a heart attack, for example. To reduce this risk TTD focuses on research into better options to determine this risk (diagnostics). TTD research can also lead to refinement of therapy and thus reduce complications and side effects. In this way TTD responds to the needs and demands of healthcare providers and the business community.
New technology (bioassays) in the field of inflammatory reactions, the testing of (nano) molecular biomarkers and novel test set-ups are used within TTD to determine the (personalised) risk of cardiovascular diseases. TTD’s open innovation platform also offers options for collaboration with the business community and knowledge staff with regard to cardiovascular disease research.
For more information we refer you to: www.grensregio.eu and www.InterregTTD.eu
Last month, the 44th Annual Conference of the European Society for Artificial Organs was held in Vienna. The conference offered a diverse program with impressive talks and fascinating posters. Andreas Blaeser, scientist at RWTH Aachen and CEO of Black Drop Biodrucker GmbH, demonstrated recent progress in 3D-bioprinting research. In the session Tissue Engineering & Regenerative Medicine, Blaeser, introduced a novel Drop-on-Demand bioprinting approach for generation of capillary-like networks. The presented technique holds great promise to facilitate fabrication of vascularized organs-on-a-chip in the near future.
Bioprinting has the potential to improve clinical research and patient care in multiple ways. After a decade of technological advancements its way to the clinics has just begun. Discover two potential ways, how patients might benefit from bioprinting technology in our CEOs recent publication.
#bioprinting, #organs_on_a_chip, #blackDrop
We are happy to announce that the publication Controlling Shear Stress in 3D-Bioprinting is a Key Factor to Balance Printing Resolution and Stem Cell Integrity was selected by Advanced Healthcare Materials to be included in one of their five new Virtual Issues that highlight recent cutting-edge research on current hot topics.
The publication will be featured in the “Biofabrication for Tissue Engineering” Issue and will be freely available for everybody to access, download, and read until the end of 2017.
Welcome to Black Drop Biodrucker GmbH. Using the blog on our webpage we keep you updated on our activities, product releases, and latest developments in the field of bioprinting.
Have Fun In the Lab and stay in touch!